USE OF A COMPUTERIZED CLINICAL DECISION SUPPORT (CCDS) TOOL IN PRIMARY CARE INCREASES RATES OF CONFIRMATORY TESTING IN PATIENTS WITH METABOLIC ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) AT RISK FOR ADVANCED LIVER FIBROSIS: A PILOT STUDY

被引：0
|
作者：
Miller, James [1 ]
Xiao, Ted [1 ]
Witek, Lauren [1 ]
Bundy, Richa [1 ]
Moses, Adam [1 ]
Obermiller, Corey [1 ]
Dharod, Ajay [1 ]
Russo, Mark [2 ]
Rudnick, Sean [3 ]
机构：
[1] Wake Forest Univ, Sch Med, Winston Salem, NC 27101 USA
[2] Carolinas Med Ctr, Charlotte, NC USA
[3] Atrium Hlth Wake Forest Baptist, Winston Salem, NC USA
来源：
HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1185
引用
收藏
页码：S903 / S904
页数：2
相关论文
共 41 条
  • [31] Prevalence, determinants, and fibrosis risk stratification of metabolic-associated fatty liver disease in a Turkish primary care setting: A retrospective study
    Arslan, Ayse Yazan
    Celik, Sultannur
    Amin, Fatuhulah
    Caylak, Ilayda
    Kesapli, Irem
    Kilic, Ibrahim Berke
    Karakullukcu, Serdar
    Ardic, Cuneyt
    Yilmaz, Yusuf
    HEPATOLOGY FORUM, 2024, 5 (02): : 63 - 67
  • [32] GLYCEMIC CONTROL PREDICTS ADVANCED FIBROSIS IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD): COMBINED DATA FROM MULTIPLE THERAPEUTIC TRIALS INCLUDING MORE THAN 4,000 LIVER BIOPSY DATA
    Rinella, Mary
    Dubourg, Julie
    Ratziu, Vlad
    Alkhouri, Naim
    Jeannin, Sophie
    Schattenberg, Joern
    Noureddin, Mazen
    Charlton, Michael
    Harrison, Stephen
    HEPATOLOGY, 2024, 80 : S649 - S650
  • [33] Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People Living With HIV Attending Centre of Excellence in HIV Care at a Tertiary Level Teaching Hospital in North India-A Pilot Study
    Ram, Ragini
    Subramanian, Anuradha
    Rajeshwari, K.
    JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PROVIDERS OF AIDS CARE, 2025, 24
  • [34] EVALUATING ACUTE HEALTHCARE UTILIZATION POST IMPLEMENTATION OF A PRIMARY CARE METABOLIC-ASSOCIATED STEATOTIC LIVER DISEASE RISK STRATIFICATION PATHWAY: A LARGE CANADIAN COHORT STUDY
    Baguley, Elizabeth
    Lee, Seungwon
    Wang, Meng
    Shaheen, Abdel-Aziz
    HEPATOLOGY, 2024, 80 : S862 - S863
  • [35] The use of ELF test, FIB-4 and sequential algorithms to screen the Type 2 Diabetes Mellitus (T2DM) population for advanced fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Pei, Yiying
    Sng, Wei Kwan
    Quah, Joanne Hui Min
    Liu, Jin
    Chong, Bee Yen
    Lee, Hwee Khim
    Wang, Xue Fei
    Tan, Ngiap Chuan
    Chang, Jason Pik Eu
    Tan, Hong Chang
    Bee, Yong Mong
    Goh, George Boon Bee
    JOURNAL OF HEPATOLOGY, 2024, 80 : S525 - S525
  • [36] Clinical utility of the Fibrosis-4 index for predicting mortality in patients with heart failure with or without metabolic dysfunction-associated steatotic liver disease: a prospective cohort study
    Boeckmans, Joost
    Prochaska, Juergen H.
    Gieswinkel, Alexander
    Boehm, Michael
    Wild, Philipp S.
    Schattenberg, Joern M.
    LANCET REGIONAL HEALTH-EUROPE, 2025, 48
  • [37] Development of a decision support tool for primary care management of patients with abnormal liver function tests without clinically apparent liver disease: a record-linkage population cohort study and decision analysis (ALFIE)
    Donnan, P. T.
    McLernon, D.
    Dillon, J. F.
    Ryder, S.
    Roderick, P.
    Sullivan, F.
    Rosenberg, W.
    HEALTH TECHNOLOGY ASSESSMENT, 2009, 13 (25) : IX - +
  • [38] Risk-stratified hepatocellular carcinoma screening according to the degree of obesity and progression to cirrhosis for diabetic patients with metabolic dysfunction-associated steatotic liver disease (MASLD) in Japan: a cost-effectiveness study
    Kowada, Akiko
    BMJ OPEN, 2024, 14 (11):
  • [39] THE STEATOSIS-ASSOCIATED FIBROSIS ESTIMATOR (SAFE) SCORE: A TOOL FOR PRIMARY CARE TO TRIAGE LOW-RISK NON-ALCOHOLIC FATTY LIVER DISEASE PATIENTS
    Sripongpun, Pimsiri
    Mannalithara, Ajitha
    Kim, Donghee
    Kwong, Allison J.
    Kim, W. Ray
    HEPATOLOGY, 2021, 74 : 53A - 54A
  • [40] Primary care sequential use of FIB-4 and the enhanced liver fibrosis test to stratify patients with non-alcoholic fatty liver disease increases cirrhosis detection and reduces referrals of patients with mild disease-2 year study analysis
    Srivastava, A.
    Gailer, R.
    Demma, S.
    Warner, A.
    Suri, D.
    Morgan, S.
    Sennett, K.
    Thorburn, D.
    Parkes, J.
    Tsochatzis, E.
    Rosenberg, W.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S68 - S68
12345